AGA Family of Websites: Gastro.org

No more surprise bills: Private insurance plans must cover the full colorectal cancer screening continuum

AGA, American Cancer Society Cancer Action Network and Fight Colorectal Cancer (CRC) urged regulators to eliminate out-of-pocket costs for patients that remain barriers to screening.

Washington, DC (January 13, 2022) – On Jan. 10, 2022, the Biden Administration issued guidance requiring private insurers to cover colonoscopy when needed as a follow-up to a non-invasive colorectal cancer screening test. This will prevent patients from receiving surprise bills for a colonoscopy when they receive a positive result from a stool-based test.  

Representatives of AGA, American Cancer Society, American Cancer Society Cancer Action Network and Fight CRC worked together to urge the Administration to make this change, including last fall meeting with regulators from the U.S. Departments of Labor, Health and Human Services, and Treasury, (which together regulate private insurance plans under the Affordable Care Act) to request they provide direction to private health plans. We applaud the Administration for supporting coverage of the full colorectal cancer screening continuum, which will improve access to life-saving screening. 

“Now patients can choose the best colorectal cancer screening test for them without fear of a surprise bill. Patients have full coverage of the full screening continuum — from an initial stool or endoscopic test to a follow-up colonoscopy. Now that the financial barriers have been eliminated, we can focus on increasing screening so we can prevent cancer deaths,” says John Inadomi, MD, president of AGA.  

The coverage guidance expands on the requirement that plans start providing the screening benefit to patients age 45+ for plan or policy years beginning on or after May 31, 2022. For health insurance plans that have already been implemented, patients need to check with their insurance provider as they may not include this coverage until next year. 

“Ensuring individuals have access to this lifesaving screening will significantly reduce suffering and death from this disease,” said Lisa Lacasse, president of the American Cancer Society Cancer Action Network (ACS CAN). “This year alone, the American Cancer Society estimates more than 150,000 individuals will be diagnosed with colorectal cancer and more than 52,000 will die from the disease. But colorectal cancer is preventable when pre-cancerous polyps are found and removed through a colonoscopy. The announcement from the Tri-Agencies clarifying all private insurance plans must fully cover colonoscopies after a positive non-invasive stool test will save lives from colon cancer. ACS CAN will work to expand this coverage to traditional Medicare and Medicaid beneficiaries to help ensure all individuals who need a colonoscopy are able to access one.” 

“Non-invasive colorectal cancer screening tests are an important tool in the fight against colorectal cancer, particularly in light of challenges patients have faced due to COVID-19, and as we expand our efforts to reach medically underserved communities,” says Anjee Davis, MPPA, president of Fight Colorectal Cancer. “This guidance will help ensure that patients can choose the test that is best for them without worrying about out-of-pocket costs. Ultimately this will save lives and support early detection of colorectal cancer.” 

Colorectal cancer remains the second leading cancer killer in the U.S. despite the availability of preventive screening options. In 2018, just 68.8% of those eligible were screened for colorectal cancer. The challenge of getting people screened was exacerbated in 2020, when it is estimated that colorectal cancer screening declined by 86% during the first few months of the COVID-19 pandemic.  

About AGA  
The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. www.gastro.org.  

AGA is now on Instagram 

Like AGA on Facebook.   
Follow us on Twitter @AmerGastroAssn  
Check out our videos on YouTube.  
Join AGA on LinkedIn. 

About Fight Colorectal Cancer 
Fight Colorectal Cancer (Fight CRC) is a leading patient-empowerment and advocacy organization in the United States, providing balanced and objective information on colon and rectal cancer research, treatment, and policy. We are relentless champions of hope, focused on funding promising, high-impact research endeavors while equipping advocates to influence legislation and policy for the collective good. Learn more at FightCRC.org 

About ACS CAN at 20  

The American Cancer Society Cancer Action Network (ACS CAN) makes cancer a top priority for policymakers at every level of government. ACS CAN empowers volunteers across the country to make their voices heard to influence evidence-based public policy change that saves lives. We believe everyone should have a fair and just opportunity to prevent, find, treat, and survive cancer. Since 2001, as the American Cancer Society’s nonprofit, nonpartisan advocacy affiliate, ACS CAN has successfully advocated for billions of dollars in cancer research funding, expanded access to quality affordable health care, and made workplaces, including restaurants and bars, smoke-free. As we mark our 20th anniversary, we’re more determined than ever to stand together with our volunteers and save more lives from cancer. Join the fight by visiting www.fightcancer.org.   

Days
Hours
Minutes
Seconds

Be part of AGA Giving Day and help the AGA Research Foundation foster and support the careers of underrepresented researchers. Donate now through Oct. 26.

AGA grants supported by Giving Day will help spark diverse students’ interest in GI research careers and launch underrepresented investigators’ academic research careers.

By using this site, you agree to our updated Privacy Policy.

X